Molecular analysis of multifocal prostate cancer by comparative genomic hybridization

Prostate

Volumn 68, Issue 16, 2008, Pages 1715-1724

  Kobayashi, Masayuki ^a   Ishida, Haruna ^b   Shindo, Takayuki ^b   Niwa, Shin Ichiro ^b   Kino, Mika ^a   Kawamura, Koji ^a   Kamiya, Naoto ^a   Imamoto, Takashi ^a   Suzuki, Hiroyoshi ^a   Hirokawa, Yoshifumi ^c   Shiraishi, Taizo ^c   Tanizawa, Tohru ^a   Nakatani, Yukio ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Link Genomics Inc   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

8p; Comparative genomic hybridization (CGH); Heterogeneity; Laser capture microdissection (LCM); Multifocal; Prostate cancer

Indexed keywords

ARTICLE; CANCER CELL; CHROMOSOME 13Q; CHROMOSOME 16Q; CHROMOSOME 2Q; CHROMOSOME 6Q; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH; CHROMOSOME 13; CHROMOSOME 16; CHROMOSOME 2; CHROMOSOME 6; CHROMOSOME 8; COMPARATIVE STUDY; DISEASE COURSE; GENETICS; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; PROSTATE TUMOR; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 8; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; MALE; NUCLEIC ACID HYBRIDIZATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 56049120804     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20832     Document Type: Article

References (51)

1. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100(11):2362-2366.
2. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 1998;83:1995-2002.
3. Bostwick DG. Grading prostate cancer. Am J Clin Pathol 1994; 102(Suppl 1):S38-S56.
4. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 1996;180:295-299.
5. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
6. Miller GJ, Cygan JM. Morphology of prostate cancer: The effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994;152(5 Pt 2):1709-1713.
7. Ruijter ET, Miller GJ, van de Kaa CA, van Bokhoven A, Bussemakers MJ, Debruyne FM, Ruiter DJ, Schalken JA. Molecular analysis of multifocal prostate cancer lesions. J Pathol 1999;188(3):271-277.
8. Konishi N, Hiasa Y, Nakamura M, Kitahori Y, Matsubara K, Nagai H. Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas. Am J Pathol 1997;150(1):305-314.
9. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, Park WS, Moon YW, Tsai ML, Linehan WM, Emmert-Buck MR, Liotta LA, Zhuang Z. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-237.
10. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147(1):92-101.
11. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007;70(4):630-633.
12. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007;67(17):7991-7995.
13. Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y, Shimazaki J. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995;13:168-174.
14. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 1996;17:225-233.
15. Komiya A, Suzuki H, Ueda T, Yatani R, Emi M, Ito H, Shimazaki J. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 1996;17:245-253.
16. Komiya A, Suzuki H, Ueda T, Aida S, Ito N, Shiraishi T, Yatani R, Emi M, Yasuda K, Shimazaki J, Ito H. PRLTS gene alterations in human prostate cancer. Jpn J Cancer Res 1997;88:389-393.
17. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Imai T, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, Ichikawa T. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997;32:205-213.
18. Kawana Y, Ichikawa T, Suzuki H, Ueda T, Komiya A, Ichikawa Y, Furuya Y, Akakura K, Igarashi T, Ito H. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 2002;53:60-64.
19. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda K, Ito H. Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 1997;20:140-147.
20. Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T, Watanabe M, Shiraishi T, Masai M, Igarashi T, Ito H. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 1999;24:183-190.
21. Ueda T, Komiya A, Suzuki H, Shimbo M, Sakamoto S, Imamoto T, Akakura K, Shiraishi T, Ichikawa T. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Prostate 2005;64:265-271.
22. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-821.
23. Kallionemi OP, Kallionemi A, Piper J, Isola J, Waldman FM, Gray WJ, Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-243.
24. Fukasawa S, Kino M, Kobayashi M, Suzuki H, Komiya A, Imamoto T, Hirokawa Y, Shiraishi T, Takiguchi M, Ishida H, Shindo T, Seki N, Ichikawa T. Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization. Prostate Cancer Prostatic Dis 2007; October 9 [Epub ahead of print].
25. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
26. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, Albertson DG. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29(3):263-264.
27. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmüller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci 1999;96(8):4494-4499.
28. Cavalli IJ, Mattevi MS, Erdtmann B, Sbalqueiro IJ, Maia NA. Equivalence of the total constitutive heterochromatin content by an interchromosomal compensation in the C band sizes of chromosomes 1, 9, 16, and Y in Caucasian and Japanese individuals. Hum Hered 1985;35(6):379-87.
29. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56(5):823-827.
30. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007;67(7):692-700.
31. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56(13):3091-3102.
32. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996;56:4150-4153.
33. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL, Frierson HF Jr, Dong JT. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 2002;34:306-312.
34. Konishi N, Nakamura M, Kishi M, Ishida E, Shimada K, Matsuyoshi S, Nagai H, Emi M. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 2003;94:764-768.
35. Wiklund F, Jonsson BA, Göransson I, Bergh A, Grönberg H. Linkage analysis of prostate cancer susceptibility: Confirmation of linkage at 8p22-23. Hum Genet 2003;112(4):414-418.
36. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996;35(1):55-65.
37. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-325.
38. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
39. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM. Allelic loss on chromosome 8p12-21in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995;55(14):2959-2962.
40. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996;56:2411-2416.
41. Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hägarth L, Kudren D, Naito K, Bergerheim US, Ekman P. Deletion on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 2001;7:3139-3143.
42. Ribeiro FR, Diep CB, Jerónimo C, Henrique R, Lopes C, Eknaes M, Lingjaerde OC, Lothe RA, Teixeira MR. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006;45(2):154-163.
43. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 2001;46(3):184-190.
44. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57(3):524-531.
45. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997;3(10):1867-1872.
46. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Decreased Ecadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54(14):3929- 3933.
47. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-938.
48. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
49. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-294.
50. Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB. Tumour-suppressor genes in prostatic oncogenesis: A positional approach. Br J Urol 1997;79:28-36.
51. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996;35:55-65.